Cargando…

MON-LB097 The Genomic Landscape of Preoperative FNAs Positive for the Afirma GSC Medullary Thyroid Cancer Classifier

Background The Afirma Genomic Sequencing Classifier (GSC) uses RNA sequencing to assess FNA specimens from cytologically indeterminate thyroid nodules, which are also tested for specific molecular aberrations associated with thyroid cancer via a suite of highly accurate malignancy classifiers. This...

Descripción completa

Detalles Bibliográficos
Autores principales:	Waguespack, Steven, Busaidy, Naifa, Hu, Mimi, Grubbs, Elizabeth, Weitzman, Steven, Wirth, Lori, Zafereo, Mark, Babiarz, Joshua, Hao, Yangyang, Huang, Jing, Kennedy, Giulia, Walsh, P. Sean, Kloos, Richard
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Endocrine Society 2019
Materias:	Thyroid
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6550928/ http://dx.doi.org/10.1210/js.2019-MON-LB097

Ejemplares similares

MON-525 ATA and ACR TIRADS Classification Systems as Additional Predictors of Malignancy in Afirma GSC Suspicious Thyroid Nodules
por: Azaryan, Irina, et al.
Publicado: (2020)

LBSAT255 Real World Performance Of The Afirma Genomic Sequencing Classifier (GSC) - A Meta-analysis
por: Nasr, Christian E, et al.
Publicado: (2022)

MON-LB88 Positive Predictive Value of TP53 Variants in Bethesda III/IV Thyroid Fine-Needle Aspirates
por: Livhits, Masha J, et al.
Publicado: (2020)

MON-LB015 Sporadic MTC in Children: Characterization of a Rare Disease
por: Gammons, Sarah, et al.
Publicado: (2020)

THU678 Real-world Performance Of Afirma Genomic Sequencing Classifier (GSC) In A Community Healthcare Setting
por: Master, Vidisha, et al.
Publicado: (2023)

MON-554 Brain Metastases in Thyroid Cancer: Molecular Profile and Institutional Experience of a Single Tertiary Referral Center in the Era of Kinase Inhibitor Therapy
por: Agosto Salgado, Sarimar, et al.
Publicado: (2019)

SUN-LB097 Thyroid Hormone Resistance Simulating Graves Disease
por: Ballestas-Revollo, Martha, et al.
Publicado: (2019)

MON-491 TRK-Fusion Thyroid Cancer: A Clinical Overview in a Large Population at a Single Cancer Center
por: Fazeli, Sasan, et al.
Publicado: (2020)

Afirma Genomic Sequencing Classifier and Xpression Atlas Molecular Findings in Consecutive Bethesda III-VI Thyroid Nodules
por: Hu, Mimi I, et al.
Publicado: (2021)

Neoadjuvant selpercatinib for advanced medullary thyroid cancer
por: Jozaghi, Yelda, et al.
Publicado: (2020)

PSAT385 Single Center Experience with the Combination of Lenvatinib and Pembrolizumab for the Treatment of Anaplastic Thyroid Cancer
por: Vodopivec, Danica M, et al.
Publicado: (2022)

Real-World Performance of the Afirma Genomic Sequencing Classifier (GSC)—A Meta-analysis
por: Nasr, Christian E, et al.
Publicado: (2022)

Preoperative Identification of Medullary Thyroid Carcinoma (MTC): Clinical Validation of the Afirma MTC RNA-Sequencing Classifier
por: Randolph, Gregory W., et al.
Publicado: (2022)

MON-518 Institutional Experience with Cytologically Indeterminate Thyroid Nodules: No Molecular Testing Versus Afirma Gene Expression Classifier or Genomic Sequencing Classifier
por: Polavarapu, Preethi, et al.
Publicado: (2020)

OR28-04 Identification of Novel and Rare Receptor Tyrosine Kinase Fusions in Thyroid Fine Needle Aspirates
por: Wirth, Lori J, et al.
Publicado: (2020)

SAT-LB097 The Effect of (131)I Treatment on Pregnancy Outcomes after Thyroidectomy in Patients with Differentiated Thyroid Carcinoma: A Meta-Analysis
por: Zhang, Lijuan, et al.
Publicado: (2019)

OR27-6 Combination Vemurafenib (BRAF Inhibitor)/Cobimetinib (MEK Inhibitor)/Atezolizumab (Anti-PDL1 Inhibitor) in BRAF-V600E Mutated Anaplastic Thyroid Cancer (ATC): Initial Safety and Feasibility
por: Cabanillas, Maria, et al.
Publicado: (2019)

MON-LB75 Stratifying the Risk of Malignancy in Indeterminate Thyroid Nodules
por: Imam, Shahnawaz, et al.
Publicado: (2020)

MON-LB095 Thyroid Nodule Localization as a Predictor Factor for Malignancy
por: Sibai, Zakaria, et al.
Publicado: (2019)

MON-LB101 Pharmacokinetics of Liothyronine during Thyroid Hormone Therapy Withdrawal
por: Celi, Francesco, et al.
Publicado: (2019)

MON-LB77 Inhibitors of XIAP as Novel Therapeutic Agents in Thyroid Cancer
por: Chu, Simon, et al.
Publicado: (2020)

MON-LB78 Thyroid Nodules > 4cm: High-Risk for Malignancy or Not?
por: Fishel, Heather, et al.
Publicado: (2020)

MON-LB85 Aberrant Glycan Expression Changes With the Phenotype of Follicular Thyroid Tumours
por: Lee, Kai Yin, et al.
Publicado: (2020)

SUN-LB82 Coexistence of Medullary Thyroid Cancer With Graves Disease: A Case Report
por: Okoli, Ogochukwu, et al.
Publicado: (2020)

Larotrectinib Before Initial Radioactive Iodine Therapy in Pediatric TRK Fusion–Positive Papillary Thyroid Carcinoma: Time to Reconsider the Treatment Paradigm for Distantly Metastatic Disease?
por: Waguespack, Steven G., et al.
Publicado: (2022)

Comparison of Afirma GEC and GSC to Nodules Without Molecular Testing in Cytologically Indeterminate Thyroid Nodules
por: Polavarapu, Preethi, et al.
Publicado: (2021)

MON-LB80 Human Thyroid Cancer Cells Are Highly Sensitive to CDK7 and 9 Inhibition
por: Rajan, Neel, et al.
Publicado: (2020)

MON-561 Medullary Thyroid Cancer in a Single Institution: Factors Associated With Biochemical Failure
por: Bettencourt-Silva, Rita, et al.
Publicado: (2019)

LBSAT290 Papillary Thyroid Cancer Discovered After Benign Afirma Gene Testing, A Case Report
por: Ahmad, Mobeen, et al.
Publicado: (2022)

LBODP097 Malignant Struma Ovarii: Long Term Successful Treatment. Outcome
por: Mandal, Kaushik, et al.
Publicado: (2022)

MON-LB094 Matrix Metalloproteinases Are Linked with Preeclampsia and May Be Useful as a Biomarker in Gestational Subclinical Hypothyroidism
por: Harumy de Lima Hirata, Andrea, et al.
Publicado: (2019)

MON-LB100 Worse Clinical Characteristics and More Unsatisfactory Therapeutic Outcomes in Coexisting Thyrotropin Pituitary Adenomas
por: Han, Huiqiao, et al.
Publicado: (2019)

MON-LB096 Methodical Aspects of Using New Low-cost Device for Bipolar Radiofrequency Ablation: Thyrablator
por: Branovan, Igor, et al.
Publicado: (2019)

MON-LB82 Plasma Expression Level of MiRNA -21 Is Related With the Presence of Papillary Thyroid Cancer
por: Zilaitiene, Birute, et al.
Publicado: (2020)

MON-LB84 Validation of TI-RADS (Thyroid Imaging, Reporting and Data System) Follow-Up Recommendations
por: Ravindra, Sindhura, et al.
Publicado: (2020)

MON-LB76 Impact of Age on Survival and Prognostic Factors in Radioiodine Refractory Differentiated Thyroid Cancer Patients
por: Buffet, Camille
Publicado: (2020)

MON-513 Suppressing the Growth of Human Medullary Thyroid Cancer Cells Using FDA-Approved Drug
por: Ramachandran, Ilangovan, et al.
Publicado: (2020)

MON-LB099 The Association between Switching from Synthroid(®) and Clinical Outcomes: Retrospective Analysis of a US Database
por: Espillat, Ramon, et al.
Publicado: (2019)

MON-LB81 Ultrasound-Guided Radiofrequency Ablation RFA of Benign Symptomatic Thyroid Nodules - Initial Colombian Experience
por: Hernandez-Triana, Eric, et al.
Publicado: (2020)

MON-562 Retrospective Analysis of Medullary Thyroid Carcinoma: Comparison between Individuals with and without RET Germline Mutation
por: Costa, Cláudia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_fbcm8henqpv93sujpqsvs7g7kq